Efficacy and Safety of Mesenchymal Stem Cells for COVID-19 Infection: A Meta-Analysis and Systematic Review.

IF 2 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Discovery medicine Pub Date : 2023-04-01 DOI:10.24976/Discov.Med.202335175.21

Li Chen, Qinfei Xu, Fen Sheng, Beibei Wang

{"title":"Efficacy and Safety of Mesenchymal Stem Cells for COVID-19 Infection: A Meta-Analysis and Systematic Review.","authors":"Li Chen, Qinfei Xu, Fen Sheng, Beibei Wang","doi":"10.24976/Discov.Med.202335175.21","DOIUrl":null,"url":null,"abstract":"Background: COVID-19 (coronavirus disease 2019) is a pandemic around the world, and its treatment options often fail to achieve ideal results. There is a lot of controversy in the treatment of COVID-19 with mesenchymal stem cells (MSCs). The study aims to assess the safety and efficacy of mesenchymal treatment of new coronary pneumonia.Methods: We manually searched electronic databases including PubMed, Embase, Cochrane Library, and Web of Science until 25th July 2022, and Stata 15.0 (StataCorpLLC: College Station, TX, USA) was used to analyze the data.Results: A total of 8 randomized controlled trials were included, involving a total of 345 people, of which 180 were in the MSCs group and 165 were in the placebo group. The analysis results showed that MSCs can reduce mortality in COVID-19 patients compared to placebo [RR (Risk Ratio) = 0.56, 95% CI (Confidence Interval) (0.36, 0.89); p = 0.003]. There was no significant difference between the mesenchymal stem cell group and the placebo group in the incidence of adverse reactions [RR = 0.64, 95% CI (0.34, 1.18); p = 0.281]; In the SpO2/FiO2 (Oxygen Saturation/Fraction of Inspiration O2) [WMD (Weighted Mean Difference) = 9.07, 95% CI (-38.01, 56.15); p = 0.080]; In ICU (Intensive Care Unit) stay [WMD = -1.66, 95% CI (-7.23, 3.91); p = 0.131].Conclusions: Mesenchymal stem cells can reduce the mortality of COVID-19 patients.","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"35 175","pages":"201-207"},"PeriodicalIF":2.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discovery medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24976/Discov.Med.202335175.21","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: COVID-19 (coronavirus disease 2019) is a pandemic around the world, and its treatment options often fail to achieve ideal results. There is a lot of controversy in the treatment of COVID-19 with mesenchymal stem cells (MSCs). The study aims to assess the safety and efficacy of mesenchymal treatment of new coronary pneumonia.

Methods: We manually searched electronic databases including PubMed, Embase, Cochrane Library, and Web of Science until 25th July 2022, and Stata 15.0 (StataCorpLLC: College Station, TX, USA) was used to analyze the data.

Results: A total of 8 randomized controlled trials were included, involving a total of 345 people, of which 180 were in the MSCs group and 165 were in the placebo group. The analysis results showed that MSCs can reduce mortality in COVID-19 patients compared to placebo [RR (Risk Ratio) = 0.56, 95% CI (Confidence Interval) (0.36, 0.89); p = 0.003]. There was no significant difference between the mesenchymal stem cell group and the placebo group in the incidence of adverse reactions [RR = 0.64, 95% CI (0.34, 1.18); p = 0.281]; In the SpO₂/FiO₂ (Oxygen Saturation/Fraction of Inspiration O₂) [WMD (Weighted Mean Difference) = 9.07, 95% CI (-38.01, 56.15); p = 0.080]; In ICU (Intensive Care Unit) stay [WMD = -1.66, 95% CI (-7.23, 3.91); p = 0.131].

Conclusions: Mesenchymal stem cells can reduce the mortality of COVID-19 patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

间充质干细胞治疗COVID-19感染的有效性和安全性:荟萃分析和系统评价

背景:COVID-19(冠状病毒病2019)是一场全球性的大流行，其治疗方案往往不能达到理想的效果。间充质干细胞(MSCs)治疗COVID-19存在诸多争议。本研究旨在评价间充质治疗新冠肺炎的安全性和有效性。方法:人工检索PubMed、Embase、Cochrane Library、Web of Science等电子数据库，检索截止日期为2022年7月25日，使用Stata 15.0软件(StataCorpLLC: College Station, TX, USA)进行数据分析。结果:共纳入8项随机对照试验，共345人，其中MSCs组180人，安慰剂组165人。分析结果显示，与安慰剂相比，MSCs可降低COVID-19患者的死亡率[RR(风险比)= 0.56,95% CI(可信区间)(0.36,0.89);P = 0.003]。间充质干细胞组与安慰剂组不良反应发生率无显著差异[RR = 0.64, 95% CI (0.34, 1.18);P = 0.281];SpO2/FiO2(氧饱和度/吸入O2分数)[WMD(加权平均差)= 9.07,95% CI (-38.01, 56.15);P = 0.080];ICU(重症监护病房)住院[WMD = -1.66, 95% CI (-7.23, 3.91);P = 0.131]。结论:间充质干细胞可降低COVID-19患者的死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Discovery medicine MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Discovery Medicine publishes novel, provocative ideas and research findings that challenge conventional notions about disease mechanisms, diagnosis, treatment, or any of the life sciences subjects. It publishes cutting-edge, reliable, and authoritative information in all branches of life sciences but primarily in the following areas: Novel therapies and diagnostics (approved or experimental); innovative ideas, research technologies, and translational research that will give rise to the next generation of new drugs and therapies; breakthrough understanding of mechanism of disease, biology, and physiology; and commercialization of biomedical discoveries pertaining to the development of new drugs, therapies, medical devices, and research technology.